Sepracor Reports Positive Data From Lunesta Trial In Generalized Anxiety
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm may be planning to expand the label for its insomnia drug.
You may also be interested in...
Sepracor Reports Promising Phase III Data For Epilepsy Compound
Late 2008/early 2009 NDA filing is targeted for eslicarbazepine as adjunct therapy for epileptic seizure control.
Sepracor Reports Promising Phase III Data For Epilepsy Compound
Late 2008/early 2009 NDA filing is targeted for eslicarbazepine as adjunct therapy for epileptic seizure control.
Sepracor Ends Xopenex Patent Battle, Seals Deals With Arrow
Acquisition of Arrow affiliate may help get Lunesta and other drugs cleared in Canada.